SEC Form 4 · accession 0001193125-26-398105
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Savage
Officer — Interim Chief Legal Officer
Period of report
Sep 18, 2026
Accepted (ET)
Sep 22, 2026 · 5:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 18, 2026 | M | 4,503 | $34.70 | A | 15,842 | D | |
| Ordinary Shares | Sep 18, 2026 | S | 4,503 | $38.69 | D | 11,339 | D | |
| Ordinary SharesF1 | Sep 18, 2026 | S | 2,525 | $39.145 | D | 8,814 | D | |
| Ordinary Shares | Sep 18, 2026 | S | 314 | $38.7038 | D | 8,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $34.70 | Sep 18, 2026 | M | 4,503 | D | — | Mar 3, 2027 | Ordinary Shares | 4,503 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.